Myovant Sciences Ltd. Common Shares (MYOV) Company Bio
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. The company was founded in 2016 and is based in Hamilton, Bermuda.
The COVID-19 pandemic has decimated the U.S. economy, yet the stock market is alive and well. Against the backdrop of a recession, the market actually had its strongest quarter in over 20 years, with the S&P 500 notching its largest quarterly gain since the last quarter of 1998, surging 20%. As for the NASDAQ, it climbed 31% higher during the quarter, marking its best quarterly performance since Q4 1999.While certainly volatile, the quarter saw investors take an optimistic approach due to reopening efforts and unprecedented stimulus packages. That being said, going forward into Q3, plenty of uncertainty is lingering over Wall Street. So, how are investors supposed to lock in on compelling plays? The Street’s pros can provide some much-needed inspiration, namely those from investment fir...
CHICAGO, Ill.; SAN MATEO, Calif.; LOS ANGELES, Calif.; and BASEL, Switzerland, June 30, 2020 (GLOBE NEWSWIRE) -- BlackDoctor.org, Evidation Health, Movember, and Myovant Sciences (NYSE: MYOV) today announced the launch of Forward Momentum, a cross-sector coalition working on innovative projects to increase diversity in research and develop new digital resources for men with prostate cancer. Prostate cancer is the second most prevalent form of cancer and second leading cause of cancer death in men in the U.S. More than 3 million men have been diagnosed with prostate cancer in the U.S. and more than 33,000 deaths are expected in 2020, with Black men twice as likely to die from the disease.